Cargando…

Non-viral precision T cell receptor replacement for personalized cell therapy

T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells(1–3). Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision genome-editing to simultaneously knockout the two endogenous TCR genes TRAC (which encodes TCRα) and TRBC (which encod...

Descripción completa

Detalles Bibliográficos
Autores principales: Foy, Susan P., Jacoby, Kyle, Bota, Daniela A., Hunter, Theresa, Pan, Zheng, Stawiski, Eric, Ma, Yan, Lu, William, Peng, Songming, Wang, Clifford L., Yuen, Benjamin, Dalmas, Olivier, Heeringa, Katharine, Sennino, Barbara, Conroy, Andy, Bethune, Michael T., Mende, Ines, White, William, Kukreja, Monica, Gunturu, Swetha, Humphrey, Emily, Hussaini, Adeel, An, Duo, Litterman, Adam J., Quach, Boi Bryant, Ng, Alphonsus H. C., Lu, Yue, Smith, Chad, Campbell, Katie M., Anaya, Daniel, Skrdlant, Lindsey, Huang, Eva Yi-Hsuan, Mendoza, Ventura, Mathur, Jyoti, Dengler, Luke, Purandare, Bhamini, Moot, Robert, Yi, Michael C., Funke, Roel, Sibley, Alison, Stallings-Schmitt, Todd, Oh, David Y., Chmielowski, Bartosz, Abedi, Mehrdad, Yuan, Yuan, Sosman, Jeffrey A., Lee, Sylvia M., Schoenfeld, Adam J., Baltimore, David, Heath, James R., Franzusoff, Alex, Ribas, Antoni, Rao, Arati V., Mandl, Stefanie J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768791/
https://www.ncbi.nlm.nih.gov/pubmed/36356599
http://dx.doi.org/10.1038/s41586-022-05531-1
_version_ 1784854249845293056
author Foy, Susan P.
Jacoby, Kyle
Bota, Daniela A.
Hunter, Theresa
Pan, Zheng
Stawiski, Eric
Ma, Yan
Lu, William
Peng, Songming
Wang, Clifford L.
Yuen, Benjamin
Dalmas, Olivier
Heeringa, Katharine
Sennino, Barbara
Conroy, Andy
Bethune, Michael T.
Mende, Ines
White, William
Kukreja, Monica
Gunturu, Swetha
Humphrey, Emily
Hussaini, Adeel
An, Duo
Litterman, Adam J.
Quach, Boi Bryant
Ng, Alphonsus H. C.
Lu, Yue
Smith, Chad
Campbell, Katie M.
Anaya, Daniel
Skrdlant, Lindsey
Huang, Eva Yi-Hsuan
Mendoza, Ventura
Mathur, Jyoti
Dengler, Luke
Purandare, Bhamini
Moot, Robert
Yi, Michael C.
Funke, Roel
Sibley, Alison
Stallings-Schmitt, Todd
Oh, David Y.
Chmielowski, Bartosz
Abedi, Mehrdad
Yuan, Yuan
Sosman, Jeffrey A.
Lee, Sylvia M.
Schoenfeld, Adam J.
Baltimore, David
Heath, James R.
Franzusoff, Alex
Ribas, Antoni
Rao, Arati V.
Mandl, Stefanie J.
author_facet Foy, Susan P.
Jacoby, Kyle
Bota, Daniela A.
Hunter, Theresa
Pan, Zheng
Stawiski, Eric
Ma, Yan
Lu, William
Peng, Songming
Wang, Clifford L.
Yuen, Benjamin
Dalmas, Olivier
Heeringa, Katharine
Sennino, Barbara
Conroy, Andy
Bethune, Michael T.
Mende, Ines
White, William
Kukreja, Monica
Gunturu, Swetha
Humphrey, Emily
Hussaini, Adeel
An, Duo
Litterman, Adam J.
Quach, Boi Bryant
Ng, Alphonsus H. C.
Lu, Yue
Smith, Chad
Campbell, Katie M.
Anaya, Daniel
Skrdlant, Lindsey
Huang, Eva Yi-Hsuan
Mendoza, Ventura
Mathur, Jyoti
Dengler, Luke
Purandare, Bhamini
Moot, Robert
Yi, Michael C.
Funke, Roel
Sibley, Alison
Stallings-Schmitt, Todd
Oh, David Y.
Chmielowski, Bartosz
Abedi, Mehrdad
Yuan, Yuan
Sosman, Jeffrey A.
Lee, Sylvia M.
Schoenfeld, Adam J.
Baltimore, David
Heath, James R.
Franzusoff, Alex
Ribas, Antoni
Rao, Arati V.
Mandl, Stefanie J.
author_sort Foy, Susan P.
collection PubMed
description T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells(1–3). Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision genome-editing to simultaneously knockout the two endogenous TCR genes TRAC (which encodes TCRα) and TRBC (which encodes TCRβ). We also inserted into the TRAC locus two chains of a neoantigen-specific TCR (neoTCR) isolated from circulating T cells of patients. The neoTCRs were isolated using a personalized library of soluble predicted neoantigen–HLA capture reagents. Sixteen patients with different refractory solid cancers received up to three distinct neoTCR transgenic cell products. Each product expressed a patient-specific neoTCR and was administered in a cell-dose-escalation, first-in-human phase I clinical trial (NCT03970382). One patient had grade 1 cytokine release syndrome and one patient had grade 3 encephalitis. All participants had the expected side effects from the lymphodepleting chemotherapy. Five patients had stable disease and the other eleven had disease progression as the best response on the therapy. neoTCR transgenic T cells were detected in tumour biopsy samples after infusion at frequencies higher than the native TCRs before infusion. This study demonstrates the feasibility of isolating and cloning multiple TCRs that recognize mutational neoantigens. Moreover, simultaneous knockout of the endogenous TCR and knock-in of neoTCRs using single-step, non-viral precision genome-editing are achieved. The manufacture of neoTCR engineered T cells at clinical grade, the safety of infusing up to three gene-edited neoTCR T cell products and the ability of the transgenic T cells to traffic to the tumours of patients are also demonstrated.
format Online
Article
Text
id pubmed-9768791
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-97687912022-12-21 Non-viral precision T cell receptor replacement for personalized cell therapy Foy, Susan P. Jacoby, Kyle Bota, Daniela A. Hunter, Theresa Pan, Zheng Stawiski, Eric Ma, Yan Lu, William Peng, Songming Wang, Clifford L. Yuen, Benjamin Dalmas, Olivier Heeringa, Katharine Sennino, Barbara Conroy, Andy Bethune, Michael T. Mende, Ines White, William Kukreja, Monica Gunturu, Swetha Humphrey, Emily Hussaini, Adeel An, Duo Litterman, Adam J. Quach, Boi Bryant Ng, Alphonsus H. C. Lu, Yue Smith, Chad Campbell, Katie M. Anaya, Daniel Skrdlant, Lindsey Huang, Eva Yi-Hsuan Mendoza, Ventura Mathur, Jyoti Dengler, Luke Purandare, Bhamini Moot, Robert Yi, Michael C. Funke, Roel Sibley, Alison Stallings-Schmitt, Todd Oh, David Y. Chmielowski, Bartosz Abedi, Mehrdad Yuan, Yuan Sosman, Jeffrey A. Lee, Sylvia M. Schoenfeld, Adam J. Baltimore, David Heath, James R. Franzusoff, Alex Ribas, Antoni Rao, Arati V. Mandl, Stefanie J. Nature Article T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells(1–3). Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision genome-editing to simultaneously knockout the two endogenous TCR genes TRAC (which encodes TCRα) and TRBC (which encodes TCRβ). We also inserted into the TRAC locus two chains of a neoantigen-specific TCR (neoTCR) isolated from circulating T cells of patients. The neoTCRs were isolated using a personalized library of soluble predicted neoantigen–HLA capture reagents. Sixteen patients with different refractory solid cancers received up to three distinct neoTCR transgenic cell products. Each product expressed a patient-specific neoTCR and was administered in a cell-dose-escalation, first-in-human phase I clinical trial (NCT03970382). One patient had grade 1 cytokine release syndrome and one patient had grade 3 encephalitis. All participants had the expected side effects from the lymphodepleting chemotherapy. Five patients had stable disease and the other eleven had disease progression as the best response on the therapy. neoTCR transgenic T cells were detected in tumour biopsy samples after infusion at frequencies higher than the native TCRs before infusion. This study demonstrates the feasibility of isolating and cloning multiple TCRs that recognize mutational neoantigens. Moreover, simultaneous knockout of the endogenous TCR and knock-in of neoTCRs using single-step, non-viral precision genome-editing are achieved. The manufacture of neoTCR engineered T cells at clinical grade, the safety of infusing up to three gene-edited neoTCR T cell products and the ability of the transgenic T cells to traffic to the tumours of patients are also demonstrated. Nature Publishing Group UK 2022-11-10 2023 /pmc/articles/PMC9768791/ /pubmed/36356599 http://dx.doi.org/10.1038/s41586-022-05531-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Foy, Susan P.
Jacoby, Kyle
Bota, Daniela A.
Hunter, Theresa
Pan, Zheng
Stawiski, Eric
Ma, Yan
Lu, William
Peng, Songming
Wang, Clifford L.
Yuen, Benjamin
Dalmas, Olivier
Heeringa, Katharine
Sennino, Barbara
Conroy, Andy
Bethune, Michael T.
Mende, Ines
White, William
Kukreja, Monica
Gunturu, Swetha
Humphrey, Emily
Hussaini, Adeel
An, Duo
Litterman, Adam J.
Quach, Boi Bryant
Ng, Alphonsus H. C.
Lu, Yue
Smith, Chad
Campbell, Katie M.
Anaya, Daniel
Skrdlant, Lindsey
Huang, Eva Yi-Hsuan
Mendoza, Ventura
Mathur, Jyoti
Dengler, Luke
Purandare, Bhamini
Moot, Robert
Yi, Michael C.
Funke, Roel
Sibley, Alison
Stallings-Schmitt, Todd
Oh, David Y.
Chmielowski, Bartosz
Abedi, Mehrdad
Yuan, Yuan
Sosman, Jeffrey A.
Lee, Sylvia M.
Schoenfeld, Adam J.
Baltimore, David
Heath, James R.
Franzusoff, Alex
Ribas, Antoni
Rao, Arati V.
Mandl, Stefanie J.
Non-viral precision T cell receptor replacement for personalized cell therapy
title Non-viral precision T cell receptor replacement for personalized cell therapy
title_full Non-viral precision T cell receptor replacement for personalized cell therapy
title_fullStr Non-viral precision T cell receptor replacement for personalized cell therapy
title_full_unstemmed Non-viral precision T cell receptor replacement for personalized cell therapy
title_short Non-viral precision T cell receptor replacement for personalized cell therapy
title_sort non-viral precision t cell receptor replacement for personalized cell therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768791/
https://www.ncbi.nlm.nih.gov/pubmed/36356599
http://dx.doi.org/10.1038/s41586-022-05531-1
work_keys_str_mv AT foysusanp nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT jacobykyle nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT botadanielaa nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT huntertheresa nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT panzheng nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT stawiskieric nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT mayan nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT luwilliam nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT pengsongming nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT wangcliffordl nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT yuenbenjamin nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT dalmasolivier nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT heeringakatharine nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT senninobarbara nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT conroyandy nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT bethunemichaelt nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT mendeines nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT whitewilliam nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT kukrejamonica nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT gunturuswetha nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT humphreyemily nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT hussainiadeel nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT anduo nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT littermanadamj nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT quachboibryant nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT ngalphonsushc nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT luyue nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT smithchad nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT campbellkatiem nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT anayadaniel nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT skrdlantlindsey nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT huangevayihsuan nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT mendozaventura nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT mathurjyoti nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT denglerluke nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT purandarebhamini nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT mootrobert nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT yimichaelc nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT funkeroel nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT sibleyalison nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT stallingsschmitttodd nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT ohdavidy nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT chmielowskibartosz nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT abedimehrdad nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT yuanyuan nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT sosmanjeffreya nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT leesylviam nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT schoenfeldadamj nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT baltimoredavid nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT heathjamesr nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT franzusoffalex nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT ribasantoni nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT raoarativ nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy
AT mandlstefaniej nonviralprecisiontcellreceptorreplacementforpersonalizedcelltherapy